Tearsheet

NewAmsterdam Pharma (NAMS)

Market Price (10/31/2025): $38.69 | Market Cap: $4.6 Bil
Sector: Health Care | Industry: Biotechnology

NewAmsterdam Pharma (NAMS)

Market Price (10/31/2025): $38.69
Market Cap: $4.6 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -16%	Trading close to highs Dist 52W High is -4.3%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -175 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -273%
1	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 762%		Expensive valuation multiples P/SPrice/Sales ratio is 72x
2	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -40%		Stock price has recently run up significantly 12M Rtn12 month market price return is 115%
3			Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -194%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -194%
4			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.1%

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -16%
1	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 762%
2	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -40%
3	Trading close to highs Dist 52W High is -4.3%
4	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -175 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -273%
5	Expensive valuation multiples P/SPrice/Sales ratio is 72x
6	Stock price has recently run up significantly 12M Rtn12 month market price return is 115%
7	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -194%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -194%
8	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.1%

Market Valuation & Key Metrics

Valuation
Key Metrics

	10/31/25	2024	2023	2022	2021
Share Price CYE	$38.69	$25.70	$11.17	$10.90
Market Cap CYE ($ Bil)	4.6	2.6	0.9	1.3	-
Total Debt ($ Bil)	0.0	0.0	0.0	0.0	0.0
Total Cash ($ Bil)	0.7	0.8	0.3	0.5	0.1
Enterprise Value ($ Bil)	3.8	2.6	0.9	1.3
Valuation Ratios
P/S TTM	71.7	53.2	65.1	2.0	0.0
P/EBIT TTM	-19.1	-10.0	-5.2	-9.2	0.0
P/E TTM	-27.7	-10.0	-5.2	-9.1	0.0
Sector Ratios
P/S TTM (Sector)	4.0	3.5	4.0	4.5	7.3
P/EBIT TTM (Sector)	-1.6	-1.3	-1.4	-1.3	-2.7
P/E TTM (Sector)	-2.0	-1.5	-1.5	-1.3	-2.8

	10/31/25	2024	2023
Share Price CYE	$38.69	$25.70	$11.17
Market Cap CYE ($ Bil)	4.6	2.6	0.9
Total Debt ($ Bil)	0.0	0.0	0.0
Total Cash ($ Bil)	0.7	0.8	0.3
Enterprise Value ($ Bil)	3.8	2.6	0.9
Valuation Ratios
P/S TTM	71.7	53.2	65.1
P/EBIT TTM	-19.1	-10.0	-5.2
P/E TTM	-27.7	-10.0	-5.2
Sector Ratios
P/S TTM (Sector)	4.0	3.5	4.0
P/EBIT TTM (Sector)	-1.6	-1.3	-1.4
P/E TTM (Sector)	-2.0	-1.5	-1.5

	NAMS	S&P 500
REVENUE GROWTH	VERY GOOD
Rev LTM ($ Bil)	0.1
Rev Chg Q	740.1%	6.4%
Rev Chg LTM	762.1%	5.4%
Rev Chg 3Y Avg	762.1%	5.3%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.2
CFO LTM ($ Bil)	-0.1
Net Inc LTM ($ Bil)	-0.2
Op Mgn LTM	-273.2%	18.7%
CFO/Rev LTM	-193.9%	20.4%
Net Inc Mgn	-258.9%	12.8%
VALUATION	VERY HIGH
P/S	71.7	3.2
P/CFO	-37.0	15.5
P/FCF	-36.9	20.6
P/E	-27.7	23.6
STABILITY	VERY GOOD
Debt/Equity	0.00	0.21
Cash/Assets	0.91	0.07

NAMS Stock

Return (1M):

Factor Drivers of Stock Movement

The 77.5% change in NAMS stock from 7/31/2025 to 10/30/2025 was primarily driven by a 35.8% change in the company's Total Revenues ($ Mil).

	7312025	10302025	Change
Stock Price ($)	21.81	38.72	77.53%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	47.14	64.01	35.78%
P/S Multiple	53.73	71.72	33.49%
Shares Outstanding (Mil)	116.12	118.56	-2.09%
Cumulative Contribution			77.46%

LTM = Last Twelve Months as of date shown

The 93.3% change in NAMS stock from 5/1/2025 to 10/30/2025 was primarily driven by a 64.1% change in the company's P/S Multiple.

	5012025	10302025	Change
Stock Price ($)	20.03	38.72	93.31%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	45.56	64.01	40.48%
P/S Multiple	43.71	71.72	64.08%
Shares Outstanding (Mil)	99.43	118.56	-19.23%
Cumulative Contribution			86.16%

LTM = Last Twelve Months as of date shown

The 115.1% change in NAMS stock from 10/30/2024 to 10/30/2025 was primarily driven by a 762.1% change in the company's Total Revenues ($ Mil).

	10302024	10302025	Change
Stock Price ($)	18.00	38.72	115.11%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	7.42	64.01	762.15%
P/S Multiple	229.63	71.72	-68.77%
Shares Outstanding (Mil)	94.71	118.56	-25.18%
Cumulative Contribution			101.48%

LTM = Last Twelve Months as of date shown

null

null

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
NAMS Return	-	-	-	2%	130%	51%	228%
Peers Return	-15%	-9%	-6%	-3%	-3%	-16%	-43%
S&P 500 Return	16%	27%	-19%	24%	23%	16%	110%
Monthly Win Rates [3]
NAMS Win Rate	-	-	100%	42%	67%	33%
Peers Win Rate	18%	15%	23%	31%	22%	51%
S&P 500 Win Rate	58%	75%	42%	67%	75%	67%
Max Drawdowns [4]
NAMS Max Drawdown	-	-	-	-45%	0%	-42%
Peers Max Drawdown	-20%	-13%	-14%	-15%	-30%	-27%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: VRTX, APM, BBOT, GDTC, HIND.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/30/2025 (YTD)

How Low Can It Go

Unique Key	Event	NAMS	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-66.2%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	196.2%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	86 days	464 days

Compare to VRTX, APM, BBOT, GDTC, HIND

In The Past

NewAmsterdam Pharma's stock fell -66.2% during the 2022 Inflation Shock from a high on 1/30/2023. A -66.2% loss requires a 196.2% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About NewAmsterdam Pharma (NAMS)

Business Description

Better Bets than NewAmsterdam Pharma (NAMS)

	NAMS	Better Performance than NAMS
Metric	Value	Industry (Biotechnology)
Rev Chg LTM	762.1%	MDGL (3422.0%), CYTK (2635.7%), ARWR (2816.2%), IBRX (4227.2%), STOK (1218.8%)
Op Mgn LTM	-273.2%	ABBV (23.5%), AMGN (23.5%), GILD (37.4%), VRTX (-1.7%), REGN (26.7%)
CFO/Rev LTM	-193.9%	ABBV (33.1%), AMGN (34.4%), GILD (34.2%), VRTX (33.7%), REGN (35.6%)
FCF/Rev LTM	-194.2%	ABBV (31.3%), AMGN (30.4%), GILD (32.5%), VRTX (30.6%), REGN (27.2%)
Total Yield	-3.6%	ABBV (3.7%), AMGN (7.4%), GILD (7.0%), VRTX (3.4%), REGN (7.2%)

	NAMS	Better Performance than NAMS
Metric	Value	Sector (Health Care)
Rev Chg LTM	762.1%	MDGL (3422.0%), CYTK (2635.7%), ARWR (2816.2%), IBRX (4227.2%), STOK (1218.8%)
Op Mgn LTM	-273.2%	LLY (43.0%), JNJ (26.2%), ABBV (23.5%), UNH (6.1%), ABT (17.6%)
CFO/Rev LTM	-193.9%	LLY (20.5%), JNJ (26.3%), ABBV (33.1%), UNH (4.8%), ABT (20.8%)
FCF/Rev LTM	-194.2%	LLY (-0.1%), JNJ (20.3%), ABBV (31.3%), UNH (4.0%), ABT (15.8%)
Total Yield	-3.6%	LLY (2.5%), JNJ (8.2%), ABBV (3.7%), UNH (8.1%), ABT (8.3%)

	NAMS	Better Performance than NAMS
Metric	Value	All Other Sectors
Rev Chg LTM	762.1%	QXO (3313.1%), UEC (29737.9%), IVR (1091.9%), ABAT (1149.0%), HYLN (3559.4%)
Op Mgn LTM	-273.2%	NVDA (58.1%), AAPL (31.9%), MSFT (46.3%), GOOGL (32.2%), AMZN (11.4%)
CFO/Rev LTM	-193.9%	NVDA (46.6%), AAPL (26.6%), MSFT (50.0%), GOOGL (39.3%), AMZN (18.1%)
FCF/Rev LTM	-194.2%	NVDA (43.6%), AAPL (23.5%), MSFT (26.6%), GOOGL (19.1%), AMZN (2.0%)
Total Yield	-3.6%	NVDA (1.8%), AAPL (2.8%), MSFT (3.3%), GOOGL (3.9%), AMZN (3.0%)

		Best Bets In Health Care Sector
	NAMS	RPRX	HALO	CPRX	BMY	LNTH	PBH	BIIB	PFE	EW	ILMN
What You Pay
P/E	-27.7	15.3	14.1	12.3	15.4	14.0	14.0	13.6	12.8	11.8	12.4
P/EBIT	-19.1	8.1	11.0	10.5	9.3	9.6	9.0	10.1	10.3	29.2	10.3
What You Get
Rev Chg Q	740.1%	7.7%	40.8%	19.4%	2.8%	-4.1%	-6.6%	2.8%	10.3%	11.9%	-4.8%
Rev Chg LTM	762.1%	3.0%	35.0%	28.5%	1.3%	5.7%	0.6%	4.8%	13.5%	9.1%	-3.3%
Rev Chg 3Y Avg	�	0.8%	35.5%	49.9%	1.0%	34.3%	0.8%	-0.9%	-12.4%	3.0%	-3.0%
FCF/Rev 3Y Avg	�	113.4%	43.4%	38.9%	29.0%	26.1%	21.6%	17.0%	13.8%	11.9%	9.0%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	NewAmsterdam Pharma Stock Rallied 35% - Have You Assessed the Risk	Return
2	NAMS Dip Buy Analysis
3	NewAmsterdam Pharma (NAMS) Valuation Ratios Comparison	Financials
4	NewAmsterdam Pharma Stock Up 36% in One Month, Wait For A Dip To Buy The Stock	Buy or Fear

	Title
0	ARTICLES
1	NewAmsterdam Pharma Stock Rallied 35% - Have You Assessed the Risk
2	NAMS Dip Buy Analysis
3	NewAmsterdam Pharma (NAMS) Valuation Ratios Comparison
4	NewAmsterdam Pharma Stock Up 36% in One Month, Wait For A Dip To Buy The Stock

Trade Ideas

Select past ideas related to NAMS. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy	09302025	ADMA	ADMA Biologics	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	5.9%	5.9%	-4.6%
REGN_9302025_Dip_Buyer_ValueBuy	09302025	REGN	Regeneron Pharmaceuticals	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	16.1%	16.1%	-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	09262025	HAE	Haemonetics	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	2.6%	2.6%	-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper	09192025	WAT	Waters	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	14.2%	14.2%	-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper	09052025	ISRG	Intuitive Surgical	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	15.2%	15.2%	-8.0%

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy	09302025	ADMA	ADMA Biologics	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	5.9%	5.9%	-4.6%
REGN_9302025_Dip_Buyer_ValueBuy	09302025	REGN	Regeneron Pharmaceuticals	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	16.1%	16.1%	-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	09262025	HAE	Haemonetics	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	2.6%	2.6%	-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper	09192025	WAT	Waters	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	14.2%	14.2%	-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper	09052025	ISRG	Intuitive Surgical	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	15.2%	15.2%	-8.0%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	GH	Guardant Health	27.9%	202.5%
2	GCI	Gannett	27.7%	3.8%
3	FORM	FormFactor	24.2%	34.7%
4	VIAV	Viavi Solutions	22.3%	69.3%
5	GSAT	Globalstar	22.2%	63.5%
6	MTSR	Metsera	22.1%	63729900.0%
7	PRM	Perimeter Solutions	21.1%	102.3%
8	CHRW	C.H. Robinson Worldwide	19.7%	52.6%
9	INSM	Insmed	16.3%	181.3%
10	CAH	Cardinal Health	15.4%	62.8%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	FMC	FMC	-46.5%	-66.6%
2	APLS	Apellis Pharmaceuticals	-31.0%	-35.0%
3	THRY	Thryv	-30.2%	-44.8%
4	SFM	Sprouts Farmers Market	-26.1%	-39.2%
5	IART	Integra Lifesciences	-23.5%	-47.9%
6	ITRI	Itron	-21.1%	0.4%
7	WOLF	Wolfspeed	-18.2%
8	CMG	Chipotle Mexican Grill	-18.2%	-46.1%
9	CI	Cigna	-17.4%	-9.2%
10	EME	EMCOR	-16.6%	43.0%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	INBX	Inhibrx Biosciences	176.8%	409.8%
2	PUMP	ProPetro	71.2%	16.2%
3	RNA	Avidity Biosciences	43.5%	139.6%
4	DYN	Dyne Therapeutics	42.8%	-0.0%
5	GCI	Gannett	39.3%	3.8%
6	FORM	FormFactor	38.3%	34.7%
7	MBX	MBX Biosciences	35.1%	18.2%
8	BBNX	Beta Bionics	33.8%
9	GH	Guardant Health	33.3%	202.5%
10	LUMN	Lumen Technologies	32.7%	94.7%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	PMI	Picard Medical	-75.2%	5106.3%
2	LRN	Stride	-56.1%	-35.8%
3	NTLA	Intellia Therapeutics	-52.6%	5.2%
4	FMC	FMC	-48.7%	-66.6%
5	FI	Fiserv	-47.4%	-68.3%
6	VRNS	Varonis Systems	-43.8%	-21.2%
7	THRY	Thryv	-33.4%	-44.8%
8	NFE	New Fortress Energy	-30.5%	-91.9%
9	AKBA	Akebia Therapeutics	-29.5%	10.5%
10	UAMY	United States Antimony	-28.9%	371.2%

1 Month Top Gainers

#	Ticker	Company	1M Rtn	YTD Rtn
1	PRAX	Praxis Precision Medicines	279.1%	161.2%
2	INBX	Inhibrx Biosciences	131.0%	409.8%
3	PUMP	ProPetro	99.6%	16.2%
4	DYN	Dyne Therapeutics	88.4%	-0.0%
5	VICR	Vicor	85.4%	89.2%
6	CELC	Celcuity	74.6%	503.2%
7	GLUE	Monte Rosa Therapeutics	73.5%	87.5%
8	NVTS	Navitas Semiconductor	72.1%	251.8%
9	LUMN	Lumen Technologies	70.3%	94.7%
10	BALY	Ballys	63.4%	4.1%

1 Month Top Losers

#	Ticker	Company	1M Rtn	YTD Rtn
1	PMI	Picard Medical	-62.9%	5106.3%
2	LRN	Stride	-53.8%	-35.8%
3	FMC	FMC	-51.0%	-66.6%
4	FI	Fiserv	-48.3%	-68.3%
5	NFE	New Fortress Energy	-43.6%	-91.9%
6	VG	Venture Global	-41.7%
7	OGN	Organon	-40.2%	-55.0%
8	VRNS	Varonis Systems	-39.5%	-21.2%
9	ITGR	Integer	-38.5%	-52.2%
10	LENZ	LENZ Therapeutics	-37.9%	5.5%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	GH	Guardant Health	27.9%	202.5%
2	GCI	Gannett	27.7%	3.8%
3	FORM	FormFactor	24.2%	34.7%
4	VIAV	Viavi Solutions	22.3%	69.3%
5	GSAT	Globalstar	22.2%	63.5%
6	MTSR	Metsera	22.1%	63729900.0%
7	PRM	Perimeter Solutions	21.1%	102.3%
8	CHRW	C.H. Robinson Worldwide	19.7%	52.6%
9	INSM	Insmed	16.3%	181.3%
10	CAH	Cardinal Health	15.4%	62.8%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	FMC	FMC	-46.5%	-66.6%
2	APLS	Apellis Pharmaceuticals	-31.0%	-35.0%
3	THRY	Thryv	-30.2%	-44.8%
4	SFM	Sprouts Farmers Market	-26.1%	-39.2%
5	IART	Integra Lifesciences	-23.5%	-47.9%
6	ITRI	Itron	-21.1%	0.4%
7	WOLF	Wolfspeed	-18.2%
8	CMG	Chipotle Mexican Grill	-18.2%	-46.1%
9	CI	Cigna	-17.4%	-9.2%
10	EME	EMCOR	-16.6%	43.0%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	INBX	Inhibrx Biosciences	176.8%	409.8%
2	PUMP	ProPetro	71.2%	16.2%
3	RNA	Avidity Biosciences	43.5%	139.6%
4	DYN	Dyne Therapeutics	42.8%	-0.0%
5	GCI	Gannett	39.3%	3.8%
6	FORM	FormFactor	38.3%	34.7%
7	MBX	MBX Biosciences	35.1%	18.2%
8	BBNX	Beta Bionics	33.8%
9	GH	Guardant Health	33.3%	202.5%
10	LUMN	Lumen Technologies	32.7%	94.7%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	PMI	Picard Medical	-75.2%	5106.3%
2	LRN	Stride	-56.1%	-35.8%
3	NTLA	Intellia Therapeutics	-52.6%	5.2%
4	FMC	FMC	-48.7%	-66.6%
5	FI	Fiserv	-47.4%	-68.3%
6	VRNS	Varonis Systems	-43.8%	-21.2%
7	THRY	Thryv	-33.4%	-44.8%
8	NFE	New Fortress Energy	-30.5%	-91.9%
9	AKBA	Akebia Therapeutics	-29.5%	10.5%
10	UAMY	United States Antimony	-28.9%	371.2%

Peer Comparisons for NewAmsterdam Pharma

Financials

	NAMS	VRTX	APM	BBOT	GDTC	HIND	Median
Name	NewAmste.	Vertex P.	Aptorum	BridgeBi.	CytoMed .	Vyome
Mkt Price	38.72	419.89	1.47	12.00	2.15	5.58	8.79
Mkt Cap	4.6	107.8	-	-	-	-	56.2
Rev LTM	64	11,419	-	0	-	-	64
Op Inc LTM	-175	-199	-	-93	-	-	-175
FCF LTM	-124	3,500	-	-60	-	-	-60
FCF 3Y Avg	-	1,984	-	-	-	-	1,984
CFO LTM	-124	3,846	-	-60	-	-	-60
CFO 3Y Avg	-	2,324	-	-	-	-	2,324

Growth & Margins

	NAMS	VRTX	APM	BBOT	GDTC	HIND	Median
Name	NewAmste.	Vertex P.	Aptorum	BridgeBi.	CytoMed .	Vyome
Rev Chg LTM	762.1%	10.5%	-	-	-	-	386.3%
Rev Chg 3Y Avg	-	11.0%	-	-	-	-	11.0%
Rev Chg Q	740.1%	12.1%	-	-	-	-	376.1%
QoQ Delta Rev Chg LTM	35.8%	2.9%	-	-	-	-	19.3%
Op Mgn LTM	-273.2%	-1.7%	-	-	-	-	-137.5%
Op Mgn 3Y Avg	-	26.5%	-	-	-	-	26.5%
QoQ Delta Op Mgn LTM	133.7%	2.0%	-	-	-	-	67.9%
CFO/Rev LTM	-193.9%	33.7%	-	-	-	-	-80.1%
CFO/Rev 3Y Avg	-	22.5%	-	-	-	-	22.5%
FCF/Rev LTM	-194.2%	30.6%	-	-	-	-	-81.8%
FCF/Rev 3Y Avg	-	19.2%	-	-	-	-	19.2%

Valuation

	NAMS	VRTX	APM	BBOT	GDTC	HIND	Median
Name	NewAmste.	Vertex P.	Aptorum	BridgeBi.	CytoMed .	Vyome
Mkt Cap	4.6	107.8	-	-	-	-	56.2
P/S	71.7	9.4	-	-	-	-	40.6
P/EBIT	-19.1	24.5	-	-	-	-	2.7
P/E	-27.7	29.6	-	-	-	-	1.0
P/CFO	-37.0	28.0	-	-	-	-	-4.5
Total Yield	-3.6%	3.4%	-	-	-	-	-0.1%
Dividend Yield	0.0%	0.0%	-	-	-	-	0.0%
FCF Yield 3Y Avg	-	2.1%	-	-	-	-	2.1%
D/E	0.0	0.0	-	-	-	-	0.0
Net D/E	-0.2	-0.0	-	-	-	-	-0.1

Returns

	NAMS	VRTX	APM	BBOT	GDTC	HIND	Median
Name	NewAmste.	Vertex P.	Aptorum	BridgeBi.	CytoMed .	Vyome
1M Rtn	36.1%	7.2%	-27.2%	3.6%	8.0%	7.7%	7.5%
3M Rtn	77.5%	-8.1%	-5.2%	-	14.4%	-	4.6%
6M Rtn	93.3%	-15.8%	59.8%	-	-6.5%	-	26.6%
12M Rtn	115.1%	-11.6%	5.0%	-	-3.4%	-	0.8%
3Y Rtn	-	34.6%	-76.8%	-	-	-	-21.1%
1M Excs Rtn	30.2%	2.2%	-34.2%	-1.9%	5.3%	-0.2%	1.0%
3M Excs Rtn	72.6%	-18.5%	-2.1%	-	8.1%	-	3.0%
6M Excs Rtn	71.6%	-37.6%	38.0%	-	-28.3%	-	4.9%
12M Excs Rtn	85.3%	-29.0%	-17.8%	-	-33.2%	-	-23.4%
3Y Excs Rtn	-	-41.0%	-151.9%	-	-	-	-96.5%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020
Period End	6/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Filing Date	8/6/2025	2/26/2025	2/28/2024	3/31/2023	10/18/2022	3/31/2023
Key Financials
Total Revenue	64	46	14	103	0	0
EBITDA	-240	-241	-177	-22	-41	-7
Operating Income	-175	-176	-183	-4	-35	-6
Net Income	-166	-242	-177	-23	-42	-7
EPS	-1.62	-2.56	-2.15	-1.19	-0.51	-0.09
Growth Rates
Total Revenue Growth	762.1%	223.4%	-86.3%	∞%	-	-
EBITDA Growth	-15.8%	-36.5%	-691.7%	46.0%	-522.4%	-
Operating Income Growth	18.1%	3.6%	-5043.9%	89.7%	-433.8%	-
Net Income Growth	27.8%	-36.5%	-681.7%	45.8%	-490.9%	-
Margins
EBITDA Margin	-375.0%	-530.0%	-1255.2%	-21.8%	-	-
Operating Income Margin	-273.2%	-386.9%	-1298.6%	-3.5%	-	-
Net Income Margin	-258.9%	-530.3%	-1255.8%	-22.0%	-	-
Cash & Debt
Total Cash	739	834	340	468	60	10
Total Debt	0	0	0	0	0	14
Net Debt / (Cash)	-739	-834	-340	-468	-60	5
Cash Flows
Net Cash from Operations	-124	-159	-141	11	-30	-7
Free Cash from Operations	-124	-159	-141	10	-30	-7
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1
Period End	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023
Filing Date	8/6/2025	5/8/2025	2/26/2025	11/6/2024	8/7/2024	5/8/2024	2/28/2024	11/6/2024	8/7/2023	5/8/2024
Key Financials Quarterly
Total Revenue	19	3	13	29	2	1	1	3	2	9
Ebitda	-36	-69	-112	-24	-53	-55	-51	-48	-39	-39
Operating Income	-36	-69	-46	-24	-53	-55	-57	-48	-39	-39
Net Income	-17	-40	-92	-17	-39	-94	-49	-47	-38	-42
EPS	-0.15	-0.34	-0.95	-0.18	-0.41	-1.06	-0.60	-0.57	-0.47	-0.51
Key Financials TTM
Total Revenue TTM	64	47	46	34	7	7	14	-	-	-
Ebitda TTM	-240	-257	-244	-183	-207	-194	-177	-	-	-
Operating Income TTM	-175	-192	-178	-189	-213	-200	-183	-	-	-
Net Income TTM	-166	-187	-242	-199	-229	-229	-177	-	-	-
Growth Rates Quarterly
Total Revenue Growth	740.1%	112.6%	1490.5%	889.8%	32.7%	-83.8%	-	-	-	-
EBITDA Growth	32.3%	-24.2%	-119.1%	50.6%	-34.8%	-43.6%	-	-	-	-
Operating Income Growth	32.2%	-24.2%	18.6%	50.6%	-34.8%	-43.6%	-	-	-	-
Net Income Growth	55.5%	57.8%	-86.2%	64.7%	-1.9%	-123.2%	-	-	-	-
Margins Quarterly
EBITDA Margin	-185.9%	-2312.7%	-874.5%	-81.9%	-2306.1%	-3959.1%	-6349.6%	-1641.2%	-2270.6%	-447.5%
Operating Income Margin	-186.1%	-2314.5%	-363.6%	-82.0%	-2306.9%	-3960.2%	-7105.5%	-1641.7%	-2271.3%	-447.7%
Net Income Margin	-90.7%	-1327.3%	-721.7%	-57.2%	-1711.6%	-6692.9%	-6163.8%	-1602.6%	-2230.1%	-486.9%
Cash & Debt
Total Cash	739	808	834	423	431	481	340	-	417	-
Total Debt	0	0	0	1	1	0	0	0	0	0
Net Debt / (Cash)	-739	-808	-834	-422	-430	-481	-340	-	-417	-
Cash Flows Quarterly
FCF from Operations	-38	-36	-37	-13	-54	-55	-33	-47	-29	-32
Cash Flows TTM
FCF from Operations TTM	-124	-140	-159	-154	-189	-164	-141	-	-	-
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-21.8%	-48.6%	-38.5%	-22.6%	-51.7%	-65.0%	-86.1%	-	-61.5%	-
Return on Invested Capital (ROIC) TTM
ROIC TTM	-26.7%	-33.8%	-37.0%	-44.7%	-52.4%	-58.5%	-69.1%	-	-	-

Price Behavior

Price Behavior

Market Price	$38.72
Market Cap ($ Bil)	4.6
First Trading Date	11/23/2022
Distance from 52W High	-4.3%
	50 Days	200 Days
DMA Price	$29.91	$22.87
DMA Trend	up	up
Distance from DMA	29.4%	69.3%
	3M	1YR
Volatility	66.4%	73.6%
Downside Capture	95.36	75.85
Upside Capture	341.13	138.88
Correlation (SPY)	15.0%	24.2%

NAMS Betas & Captures as of 9/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	1.86	2.45	2.82	1.06	0.97	0.24
Up Beta	4.39	3.21	3.30	0.45	0.74	0.07
Down Beta	-6.58	-0.26	0.04	1.17	1.27	0.53
Up Capture	368%	385%	519%	263%	141%	87%
Bmk +ve Days	13	23	35	74	144	420
Stock +ve Days	12	23	36	69	130	356
Down Capture	126%	200%	224%	165%	86%	93%
Bmk -ve Days	8	19	29	52	107	330
Stock -ve Days	9	19	27	54	117	339

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date	10152025
Short Interest: Shares Quantity	6,855,986
Short Interest: % Change Since 9302025	-10.3%
Average Daily Volume	1,493,276
Days-to-Cover Short Interest	4.59
Basic Shares Quantity	118,556,492
Short % of Basic Shares	5.8%

Returns Analyses

	Title
0	NewAmsterdam Pharma Stock Rallied 35% - Have You Assessed the Risk

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
8/6/2025	8.7%	15.0%	18.1%
5/8/2025	1.8%	-0.9%	6.4%
2/26/2025	10.2%	20.2%	26.2%
11/6/2024	13.7%	29.3%	-5.6%
8/7/2024	-3.5%	6.1%	-0.2%
5/9/2024	0.3%	-9.1%	-11.4%
2/28/2024	-2.5%	-8.1%	-6.3%
SUMMARY STATS
# Positive	5	4	3
# Negative	2	3	4
Median Positive	8.7%	17.6%	18.1%
Median Negative	-3.0%	-8.1%	-6.0%
Max Positive	13.7%	29.3%	26.2%
Max Negative	-3.5%	-9.1%	-11.4%

	Forward Returns
8/6/2025	8.7%	15.0%	18.1%
5/8/2025	1.8%	-0.9%	6.4%
2/26/2025	10.2%	20.2%	26.2%
11/6/2024	13.7%	29.3%	-5.6%
8/7/2024	-3.5%	6.1%	-0.2%
5/9/2024	0.3%	-9.1%	-11.4%
2/28/2024	-2.5%	-8.1%	-6.3%
SUMMARY STATS
# Positive	5	4	3
# Negative	2	3	4
Median Positive	8.7%	17.6%	18.1%
Median Negative	-3.0%	-8.1%	-6.0%
Max Positive	13.7%	29.3%	26.2%
Max Negative	-3.5%	-9.1%	-11.4%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
6302025	8062025	10-Q 6/30/2025
3312025	5082025	10-Q 3/31/2025
12312024	2262025	10-K 12/31/2024
9302024	11062024	10-Q 9/30/2024
6302024	8072024	10-Q 6/30/2024
3312024	5082024	10-Q 3/31/2024
12312023	2282024	10-K 12/31/2023
6302023	8072023	6-K 6/30/2023
12312022	3312023	20-F 12/31/2022
12312021	10182022	424B3 12/31/2021

Insider Activity

Expand for More

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

NewAmsterdam Pharma (NAMS)

Market Price (10/31/2025): $38.69 | Market Cap: $4.6 BilSector: Health Care | Industry: Biotechnology

NewAmsterdam Pharma (NAMS)

Market Price (10/31/2025): $38.69Market Cap: $4.6 BilSector: Health CareIndustry: Biotechnology

Market Valuation & Key Metrics

NAMS Stock

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About NewAmsterdam Pharma (NAMS)

Interactive Breakdown

Better Bets than NewAmsterdam Pharma (NAMS)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for NewAmsterdam Pharma

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (10/31/2025): $38.69 | Market Cap: $4.6 Bil
Sector: Health Care | Industry: Biotechnology

Market Price (10/31/2025): $38.69
Market Cap: $4.6 Bil
Sector: Health Care
Industry: Biotechnology